Published in World J Urol on September 25, 2012
Upper urinary tract disease: what we know today and unmet needs. Transl Androl Urol (2015) 0.83
Why are upper tract urothelial carcinoma two different diseases? Transl Androl Urol (2016) 0.78
Endoscopic management of upper urinary tract urothelial carcinoma. Korean J Urol (2013) 0.78
BCG-related renal granulomas managed conservatively: A case series. Can Urol Assoc J (2015) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Antegrade perfusion with bacillus Calmette-Guérin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol (2011) 3.47
European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol (2011) 2.70
Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol (2010) 1.84
13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol (1999) 1.82
Intrarenal bacillus Calmette-Guérin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure. BJU Int (2001) 1.46
Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol (1996) 1.30
Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol (1997) 1.22
A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int (2005) 1.16
A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy? Urology (2008) 1.13
Narrow-band imaging digital flexible ureteroscopy in detection of upper urinary tract transitional-cell carcinoma: initial experience. J Endourol (2011) 1.10
Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol (2000) 1.06
Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res (2001) 1.06
New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J Urol (1998) 0.99
Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol (1997) 0.97
Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol (2010) 0.97
Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol (2002) 0.96
Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J Urol (1995) 0.95
Nephrostomy tract tumor seeding following percutaneous manipulation of a ureteral carcinoma. J Urol (1995) 0.94
Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol (2000) 0.90
Broadening experience with the retrograde endoscopic management of upper urinary tract urothelial malignancies. BJU Int (2005) 0.90
Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors. J Urol (1993) 0.89
Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am (2000) 0.89
Percutaneous management of renal pelvic tumors: a treatment option in selected cases. J Urol (1987) 0.85
Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ. J Urol (1993) 0.85
Percutaneous treatment of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am (1988) 0.84
Clinical outcome of bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract. Int J Urol (2002) 0.83
The management of transitional cell carcinoma in solitary renal units. J Urol (1991) 0.83
Bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract. Br J Urol (1996) 0.82
Definitive tumor resection and percutaneous bacille Calmette-Guérin for management of renal pelvic transitional cell carcinoma in solitary kidneys. Urology (1995) 0.82
Bacillus Calmette-Guérin instillation treatment for carcinoma in situ of the upper urinary tract. BJU Int (2000) 0.82
Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol (2005) 0.80
Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro. World J Urol (1994) 0.80
Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy. Int J Urol (2006) 0.80
Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-alpha2B. J Endourol (2007) 0.80
Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ. J Urol (1989) 0.80
Ureteroscopic management of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am (1988) 0.80
Complications of intracavitary bacillus Calmette-Guerin after percutaneous resection of upper tract transitional cell carcinoma. J Urol (1994) 0.80
Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract. Urology (2004) 0.78
Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin. J Urol (1985) 0.78
The effect of bacillus Calmette-Guerin on the urinary system of pigs. J Urol (1988) 0.77
Instillation of bacillus Calmette-Guerin into the renal pelvis of a solitary kidney for the treatment of transitional cell carcinoma. J Urol (1990) 0.77
Adjuvant topical treatment of upper urinary tract urothelial tumours. BJU Int (2004) 0.76
Bacillus Calmette-Guérin for upper tract urothelial cancer: is there a role? J Endourol (2009) 0.76
Local excision and topical thiotepa in the treatment of transitional cell carcinoma of the renal pelvis: a case report. J Urol (1986) 0.75
Treatment of urothelial carcinoma of the upper urinary tract following prostatocystectomy with mitomycin C instillation in the ileal loop. J Urol (1986) 0.75
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol (2013) 6.54
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol (2011) 4.25
The clinical research office of the endourological society ureteroscopy global study: indications, complications, and outcomes in 11,885 patients. J Endourol (2013) 2.82
Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol (2008) 2.80
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol (2011) 2.43
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
Laboratory and clinical development of single keyhole umbilical nephrectomy. Urology (2007) 2.28
Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol (2011) 2.19
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15
Involvement of connexins 43 and 45 in functional mechanism of human detrusor overactivity in neurogenic bladder. Urology (2013) 2.01
Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. Eur Urol (2011) 2.00
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol (2009) 1.90
Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol (2006) 1.90
Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol (2009) 1.83
The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol (2009) 1.78
A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77
Flexible ureterorenoscopy with holmium laser in horseshoe kidneys. Urology (2010) 1.63
Laparoscopic partial nephrectomy with clamping of the renal parenchyma: initial experience. Eur Urol (2007) 1.60
Targeted therapy in renal cell carcinoma. World J Urol (2008) 1.56
Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol (2008) 1.54
Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol (2009) 1.52
Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol (2011) 1.49
Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int (2014) 1.49
Training on a virtual reality laparoscopic simulator improves performance of an unfamiliar live laparoscopic procedure. J Urol (2008) 1.48
Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate (2014) 1.48
Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors? Eur Urol (2010) 1.47
Tamsulosin hydrochloride vs placebo for management of distal ureteral stones: a multicentric, randomized, double-blind trial. Arch Intern Med (2010) 1.46
Demographics and characterization of 10,282 Randall plaque-related kidney stones: a new epidemic? Medicine (Baltimore) (2015) 1.45
Optical spectroscopy techniques can accurately distinguish benign and malignant renal tumours. BJU Int (2012) 1.45
Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma. Urology (2013) 1.44
Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. World J Urol (2013) 1.42
Long-term functional outcomes after artificial urinary sphincter implantation in women with stress urinary incontinence. BJU Int (2014) 1.42
Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol (2011) 1.42
Prostate-sparing cystectomy for bladder cancer: a step toward a dead-end. Urology (2010) 1.41
Flexible ureteroscopy and laser lithotripsy for stones >2 cm: a systematic review and meta-analysis. J Endourol (2012) 1.40
To infinity and beyond: the robotic toy story. Eur Urol (2011) 1.40
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int (2013) 1.40
[Role of endoscopy in the management of upper urinary tract tumors]. Prog Urol (2006) 1.39
Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis. BJU Int (2014) 1.39
Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol (2008) 1.35
Impact on active scope deflection and irrigation flow of all endoscopic working tools during flexible ureteroscopy. Eur Urol (2004) 1.35
The AdVance transobturator male sling for postprostatectomy incontinence: clinical results of a prospective evaluation after a minimum follow-up of 6 months. Eur Urol (2009) 1.32
Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int (2009) 1.29
EAU guidelines on laser technologies. Eur Urol (2012) 1.27
Natural history of residual fragments following percutaneous nephrostolithotomy. J Urol (2009) 1.24
Stone-free rate (SFR): a new proposal for defining levels of SFR. Urolithiasis (2013) 1.22
Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma? J Urol (2003) 1.22
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.21
Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol (2009) 1.21
Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int (2011) 1.15
Synchronous bilateral percutaneous nephrostolithotomy: analysis of clinical outcomes, cost and surgeon reimbursement. J Urol (2008) 1.13
EAU guidelines on robotic and single-site surgery in urology. Eur Urol (2013) 1.13
Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol (2011) 1.11
Percutaneous management of staghorn calculi in horseshoe kidneys: a multi-institutional experience. J Endourol (2010) 1.10
Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study. Urology (2012) 1.09
The changing evolution of renal tumours: a single center experience over a two-decade period. Eur Urol (2004) 1.06
Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology (2006) 1.04
Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int (2008) 1.03
Determinants of osteopenia in male renal-stone-disease patients with idiopathic hypercalciuria. Clin J Am Soc Nephrol (2011) 1.03
Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol (2006) 1.02
Methylated genes as potential biomarkers in prostate cancer. BJU Int (2010) 1.02
Residual fragments after percutaneous nephrolithotomy: cost comparison of immediate second look flexible nephroscopy versus expectant management. J Urol (2010) 1.01
Transperitoneal laparoscopic nephrectomy for autosomal dominant polycystic kidney disease. JSLS (2013) 1.01
Training in ureteroscopy: a critical appraisal of the literature. BJU Int (2011) 1.01
Results of the tension-free vaginal tape technique in the elderly. Eur Urol (2003) 1.00
Impact of body mass index on cost and clinical outcomes after percutaneous nephrostolithotomy. Urology (2008) 1.00
Which ureteral access sheath is compatible with your flexible ureteroscope? J Endourol (2013) 0.99
Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int (2008) 0.99
Outcomes of flexible ureterorenoscopy and laser fragmentation for renal stones: comparison between digital and conventional ureteroscope. Urology (2013) 0.99
Relationships between carbonation rate of carbapatite and morphologic characteristics of calcium phosphate stones and etiology. Urology (2009) 0.99
Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol (2011) 0.98
Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol (2011) 0.98
Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature. Cancer Treat Rev (2011) 0.98
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J Urol (2013) 0.98
Comparison of mid-term carcinologic control obtained after open, laparoscopic, and robot-assisted radical prostatectomy for localized prostate cancer. World J Urol (2009) 0.98
Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol (2010) 0.97
[Management of priapism in patients with sickle-cell anaemia]. Prog Urol (2005) 0.97
Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol (2005) 0.96
Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer? BJU Int (2010) 0.96
Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol (2012) 0.96
A prospective comparison of the pathologic and surgical outcomes obtained after elective treatment of renal cell carcinoma by open or robot-assisted partial nephrectomy. Urol Oncol (2011) 0.95
Long-term functional outcomes after ileal ureter substitution: a single-center experience. Urology (2011) 0.94
Tumor size and nephron-sparing surgery: does it still matter? Eur Urol (2007) 0.94
Assessment of basic human performance resources predicts operative performance of laparoscopic surgery. J Am Coll Surg (2003) 0.93
Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol Oncol (2009) 0.93
Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments. BJU Int (2007) 0.93